Clinical Trial Site

Charlotte, North Carolina 28287

2 studies enrolling now · 10 studies all time

What they study most

Atypical Hemolytic Uremic Syndrome, Breast Cancer, Dravet Syndrome, ER Positive Breast Cancer, Generalized Myasthenia Gravis, HER2 Negative Breast Carcinoma, Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, High Cardiovascular Risk, Hypertension, Iron Deficiency Anemia, Lennox Gastaut Syndrome, Locally Advanced Breast Cancer

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer — Recruiting now
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) — Recruiting now
• Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution — Running, not enrolling
• A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer — Completed
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA) — Completed
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery — Stopped early
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation — Completed
• Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment — Stopped early